Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced inducement equity awards granted on October 1, 2025 to 27 new non-executive employees under its 2025 Inducement Plan.
The awards, approved by the independent Compensation Committee consistent with Nasdaq Listing Rule 5635(c)(4), comprise options to purchase 1,602 shares and 10,973 time‑based restricted stock units (RSUs) in the aggregate. Option exercise price is $449.14 per share (closing price on grant date).
Vesting: options vest 25% at one year then 6.25% each quarter thereafter; RSUs vest in four equal annual installments. All vesting is conditioned on continued employment as of each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha annunciato premi azionari di induzione assegnati il 1 ottobre 2025 a 27 nuovi dipendenti non esecutivi nell'ambito del suo Piano di Induzione 2025.
I premi, approvati dal Comitato di compensazione indipendente in linea con Nasdaq Listing Rule 5635(c)(4), comprendono opzioni per acquistare 1.602 azioni e 10.973 unità di azioni ordinarie soggette a restrizioni basate sul tempo (RSU) in totale. Il prezzo di esercizio dell'opzione è di $449,14 per azione (prezzo di chiusura nel giorno di grant).
In vesting: le opzioni maturano il 25% dopo un anno, poi il 6,25% ogni trimestre successivo; le RSU maturano in quattro rate annuali uguali. Tutto il vesting è condizionato al continuo impiego al momento di ogni data di vesting.
Madrigal Pharmaceuticals (NASDAQ:MDGL) anunció premios de adquisición de acciones otorgados el 1 de octubre de 2025 a 27 nuevos empleados no directivos bajo su Plan de Inducción 2025.
Los premios, aprobados por el Comité de Compensación independiente de acuerdo con Regla 5635(c)(4) de Nasdaq Listing, comprenden opciones para comprar 1.602 acciones y 10.973 unidades de acciones restringidas basadas en el tiempo (RSU) en total. El precio de ejercicio de la opción es de $449,14 por acción (precio de cierre en la fecha de otorgamiento).
Vesting: las opciones se consolidan al 25% a los doce meses y luego al 6,25% cada trimestre; las RSU se consolidan en cuatro cuotas anuales iguales. Todo el vesting está condicionado a la continuidad del empleo en cada fecha de vesting.
Madrigal Pharmaceuticals (NASDAQ:MDGL)은 2025년 10월 1일에 27명의 신규 비임원 직원들에게 2025 Inducement Plan에 따라 inducement 주식 보상을 부여했다고 발표했다.
보상은 독립적인 보상위원회가 승인했으며 Nasdaq Listing Rule 5635(c)(4)에 부합한다. 총액은 1,602 주의 옵션과 10,973 주의 시간기반 제한 주식(RSU)으로 구성된다. 옵션의 행사가격은 주당 $449.14로 부여일의 종가를 기준으로 한다.
베스팅: 옵션은 1년 후 25%가 vest되고 이후 분기마다 6.25%씩 vesting된다; RSU는 4년 동안 매년 등분하여 vesting된다. 모든 vesting은 각 vesting 날짜에 고용이 지속되는 조건이 붙는다.
Madrigal Pharmaceuticals (NASDAQ:MDGL) a annoncé des attributions d'actions d'induction accordées le 1er octobre 2025 à 27 nouveaux employés non cadres dans le cadre de son Plan d'Induction 2025.
Les attributions, approuvées par le Comité de rémunération indépendant et conformément à Nasdaq Listing Rule 5635(c)(4), comprennent des options pour acheter 1 602 actions et 10 973 unités d'actions restreintes basées sur le temps (RSU) au total. Le prix d'exercice des options est de $449,14 par action (cours de clôture à la date d'octroi).
Vesting: les options acquièrent 25% après un an, puis 6,25% chaque trimestre par la suite; les RSU vestent en quatre versements annuels égaux. Tout le vesting est conditionné à la poursuite de l'emploi à chaque date de vesting.
Madrigal Pharmaceuticals (NASDAQ:MDGL) gab Anreiz-Aktienzuteilungen bekannt, die am 1. Oktober 2025 an 27 neue nicht-für das Management zuständige Mitarbeitende im Rahmen ihres Induktion-Plans 2025 gewährt wurden.
Die Zuteilungen, genehmigt vom unabhängigen Vergütungsausschuss und in Übereinstimmung mit Nasdaq Listing Rule 5635(c)(4), umfassen Optionen zum Kauf von 1.602 Aktien und 10.973 zeitbasierten Restricted Stock Units (RSUs) insgesamt. Ausübungspreis der Optionen beträgt $449,14 pro Aktie (Schlusskurs am Gewährungsdatum).
Vesting: Optionen fassen 25% nach einem Jahr, dann jeweils 6,25% pro Quartal; RSUs vesten in vier gleichen jährlichen Raten. Das gesamte Vesting setzt eine fortlaufende Beschäftigung zum jeweiligen Vesting-Termin voraus.
Madrigal Pharmaceuticals (NASDAQ:MDGL) أعلنت منح أسهم حوافز تم منحها في 1 أكتوبر 2025 ل27 موظفاً جديداً غير تنفيذيين في إطار خطة Inducement لعام 2025. الجوائز، التي وافق عليها لجنة التعويض المستقلة وتتواءم مع قواعد إدراج ناسداك 5635(c)(4)، تتألف من خيارات لشراء 1,602 سهم و 10,973 وحدة أسهم مقيدة زمنياً (RSUs) في الإجمال. سعر تمكين الخيار هو $449.14 للسهم الواحد (سعر الإغلاق في تاريخ المنح). الإشباع: خيارات تحصل على 25% بعد سنة، ثم 6.25% كل ربع سنة لاحقاً؛ RSUs تشطب على أربع دفعات سنوية متساوية. كل الإشباع مشروط باستمرار العمل في تاريخ الإشباع.
Madrigal Pharmaceuticals (NASDAQ:MDGL) 公布了在 2025年10月1日 授予的诱导性股票奖励，受益人包括 27 名非管理层新员工，依照其 2025 Inducement Plan 的规定。
该奖励经过独立薪酬委员会批准，符合 纳斯达克证券交易所上市规则5635(c)(4)，包含总计 1,602 股的购买期权和 10,973 股基于时间的受限股票单位（RSU）。期权行权价为每股 $449.14（授予日收盘价）。归属：期权在第一年解锁 25%，此后每季度解锁 6.25%；RSU 以同等的年度四期进行归属。所有归属均以在各自归属日仍在职为前提。
- None.
- None.
CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2025 to 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 1,602 shares of Madrigal’s common stock, and in the aggregate 10,973 time-based restricted stock units. Options have an exercise price of
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
What equity inducement did Madrigal (MDGL) grant on October 1, 2025?
What is the exercise price of the MDGL options granted as inducements?
How do the MDGL options vest for the October 1, 2025 grants?
What is the vesting schedule for the MDGL restricted stock units granted October 1, 2025?
Under what authority were the MDGL inducement awards approved?
How many employees received inducement awards from Madrigal on October 1, 2025?
